Links to external sources may no longer work as intended. The content may not represent the latest thinking in this area or the Society’s current position on the topic.
The virtues and vices of protein citrullination
Theo Murphy meeting organised by Dr Maria Christophorou.
Citrullination is emerging as a fundamental regulatory mechanism in human physiology and pathophysiology, from immunity, neurobiology and embryonic development to rheumatology, neurodegeneration and cancer. Scientists from across these fields will come together for the first time to discuss the molecular and cellular biology of citrullination, approaches for its detection and modulation, future directions and implications for health and disease.
The schedule of talks and speaker biographies are available below. Speaker abstracts are also available below. An accompanying journal issue has been published in Philosophical Transactions of the Royal Society B.
Attending this event
This event has taken place.
Enquiries: contact the Scientific Programmes team
Organisers
Schedule
Chair
Dr Louise Walport, Imperial College London and The Francis Crick Institute, UK
Dr Louise Walport, Imperial College London and The Francis Crick Institute, UK
Louise is a Lecturer in the Department of Chemistry at Imperial College London and a Group Leader at the Francis Crick Institute. In 2014, Louise obtained her doctorate from the University of Oxford under the supervision of Professor Chris Schofield and Prof. Christina Redfield, focussing on mechanistic studies of histone demethylases. Following further postdoctoral work in Oxford, she was awarded a Marie Skłodowska-Curie Global Fellowship to work in the group of Professor Hiroaki Suga at the University of Tokyo, where she developed an interest in cyclic peptides. She established her independent group in late 2018, where she continues to be interested in understanding enzyme-catalysed post-translational modifications and developing new approaches to probe these with cyclic peptide-based tools.
08:10 - 08:40 |
Is rheumatoid arthritis a disease of aberrant citrullination?
Rheumatoid arthritis (RA), an autoimmune disease with a worldwide incidence up to 0.24%, is characterized by the presence of anti-citrullinated protein antibodies. Citrullination is a unique form of post-translational modification of proteins. Its physiological roles are still not fully understood. Several major environmental and genetic risk factors of RA, such as cigarette smoking and the C1858T single nucleotide polymorphism of the PTPN22 gene, are associated with local or systemic hypercitrullination. Emerging data has demonstrated that hypercitrullination not only expands the pool of citrullinated antigens but also modulates the function of innate and adaptive immune cells, thereby directly or indirectly contributing to the pathogenesis of RA. The functional impacts and mechanisms of action of citrullination in neutrophils and T lymphocytes will be reviewed and discussed. In addition, new evidence demonstrating a critical role of citrullination in regulating the function of B lymphocytes will be presented. The audience is expected to gain a global view of how aberrant citrullination participates in various steps towards the development of RA. Dr I-Cheng Ho, Brigham and Women’s Hospital, Harvard Medical School, US
Dr I-Cheng Ho, Brigham and Women’s Hospital, Harvard Medical School, USDr. I-Cheng Ho graduated from Taipei Medical University in 1986 and earned his PhD degree at University of Michigan in 1991 under the supervision of Dr. Jeffrey Leiden. He subsequently completed his postdoctoral training at the laboratory of Dr. Laurie Glimcher at Harvard School of Public Healthy in 1997. He received his clinical training at Taipei Veterans General Hospital, University of Michigan Hospital, and Brigham and Women's Hospital. He is currently a member of American Society of Clinical Investigation, an associate professor of Harvard Medical School, a board-certified rheumatologist at Brigham and Women's Hospital. His clinical interest is in rheumatoid arthritis and his current research focus is on the physiological and pathological roles of protein citrullination, particularly in the setting of autoimmune diseases. His past and current research supports include funding from Rheumatology Research Foundation, National Health Research Institutes of Taiwan, Department of Defense, and National Institutes of Health. |
---|---|
08:40 - 08:50 |
Discussion
|
08:50 - 09:20 |
The role of citrullination in neutrophil extracellular trap-mediated signaling
Neutrophils, are key innate immune antimicrobial effector cells that were once only appreciated for their antimicrobial properties. In addition, neutrophil tune inflammation by producing their own cytokines during infection or via the release of large web-like extracellular chromatin structures called neutrophil extracellular traps (NETs) that activate macrophages, monocytes and dendritic cells. NET-mediated macrophage activation drives the early phases of atherogenesis. Protein citrullination has gained attention in NET studies due to the role of protein arginine deiminase 4 (PAD4) in histone citrullination, a process that is thought to be required for chromatin decondensation. The talk will explore how histones, DNA, citrullination, and chromatin fragmentation synergize downstream of NET formation to drive inflammation below the histone cytotoxicity threshold. The synergy between histones and DNA is critical for sub-lethal histone-mediated signaling and relies on distinct roles for citrullinated histones and DNA. Histones bind and activate TLR4, whereas DNA recruits TLR4 to histone-containing endosomes. Citrullination is dispensable for NETosis but potentiates histone-mediated signaling. Consistently, chromatin blockade or PAD4 deficiency reduces atherosclerosis. Additional pathologic functions of extracellular histones as regulators of neutrophil populations during severe infections will also be discussed. Dr Venizelos Papayannopoulos, The Francis Crick Institute, UK
Dr Venizelos Papayannopoulos, The Francis Crick Institute, UKVeni did his undergraduate studies at Rutgers University, USA (1998) working with Ken Irvine on the mechanisms that establish tissue barriers during Drosophila development. He then moved to San Francisco to pursue a PhD with Wendell Lim at the University of California San Francisco (2004), studying protein-lipid signaling in the regulation of actin dynamics. For his post-doctoral work, he joined the lab of Arturo Zychlinsky in Berlin to investigate the molecular mechanisms driving the formation of neutrophil extracellular traps before becoming a group leader at the MRC National Institute for Medical Research and later the Francis Crick Institute in 2012. |
09:20 - 09:30 | Discussion |
09:30 - 10:00 | Break |
10:00 - 10:30 |
PADI4 and hair follicle lineage progression
Stem and progenitor cell state transitions are closely controlled to enable tissue formation. How PADIs and citrullination contribute to lineage progression is largely unknown. The researchers find that PADI4 is dynamically regulated during hair follicle formation, and that PADI4 mRNA is enriched in a subset of progenitor cells in the hair bulb. Loss of PADI4 in vivo results in increased progenitor proliferation and retarded commitment to the hair shaft lineage, suggesting that PADI4 acts to balance progenitor proliferation and commitment to differentiation. Characterization of the PADI4-dependent citrullinome reveals protein targets linked to mRNA processing and translational control, and in vivo OP-Puro incorporation confirm that translation rates are increased in the absence of PADI4. Mechanistically, lack of PADI4 leads to phosphorylation of AKT and S6 whereas paradoxically, activity of the downstream translational initiator 4E-BP1 is reduced, suggesting a PADI4-dependent rewiring of the translational machinery. Collectively, the researchers' findings suggest a role for PADI4 in orchestrating hair follicle lineage progression through fine tuning of the translational landscape. Dr Maria Genander, Karolinska Institutet, Sweden
Dr Maria Genander, Karolinska Institutet, SwedenMaria’s scientific interests are centred around stem cell biology and the link to cancer. After elucidating mechanisms of intestinal stem cell proliferation during her PhD at Karolinska Institutet, Maria moved to Rockefeller University for her postdoctoral work in 2011, focusing on BMP-mediated hair follicle stem cell quiescence under the guidance of Elaine Fuchs. Maria returned to Karolinska Institutet and established her independent group in 2016, using the skin and esophageal epithelium as model systems to understand stem and tumour cell behaviour. In her talk, she will discuss some of the work that the lab is doing with regards to delineating the function of PADI4 in the hair follicle stem cell linage. |
10:30 - 10:40 | Discussion |
10:40 - 11:10 |
Citrullination in the regulation of cell fate
The discovery that somatic cells can be reprogrammed to a pluripotent state and instructed to differentiate into various cell types promises to revolutionise regenerative medicine. However, in vitro reprogramming is inefficient and we lack a clear mechanistic understanding of the reprogramming process and rational approaches to enhance its efficiency. The author discovered that the citrullinating enzyme peptidylarginine deiminase IV (PADI4) regulates the establishment of pluripotency during mammalian pre-implantation development and reprogramming of somatic cells to induced pluripotent stem (iPS) cells. In the course of reprogramming, citrullination of histone H3 is an early event that precedes the expression of pluripotency markers and the establishment of iPS colonies. Inhibition of H3 citrullination via pharmacological or genetic perturbation of PADI4 inhibits reprogramming. In addition, the researchers find that deletion of Padi4 biases lineage commitment of embryonic stem cells during differentiation. The author will discuss their unpublished work investigating how PADI4 mediates the integration of cell signalling inputs and their translation into the epigenetic and transcriptional changes that underlie cell identity transitions during embryonic development and cell reprogramming. Dr Maria Christophorou, Babraham Institute, UK
Dr Maria Christophorou, Babraham Institute, UKMaria is a biomedical scientist interested in understanding how cell signaling inputs are translated into the epigenetic changes that underlie cell fate. She studied biology at MIT as a Fulbright Scholar and obtained a PhD in cancer biology from UCSF. As a postdoctoral fellow in epigenetics at the Gurdon Institute, University of Cambridge, she identified a novel role for protein citrullination in the establishment of pluripotency and described a mechanism by which it mediates chromatin decondensation. She is currently a Principal Investigator at the Babraham Institute in Cambridge, UK. The work of her team continues to focus primarily on protein citrullination, with the aim of understanding how it is regulated, the molecular mechanisms through which it modulates cell physiology and how its deregulation impacts on disease development. Maria’s work has been funded by fellowships from EMBO, HFSP, Wellcome Trust and Royal Society. She was awarded the Wellcome-Beit Prize in 2015. |
11:10 - 11:20 | Discussion |
11:20 - 12:20 | Lunch |
Chair
Dr Kimberly Martinod, KU Leuven, Belgium
Dr Kimberly Martinod, KU Leuven, Belgium
Kimberly Martinod is an assistant professor in the Department of Cardiovascular Sciences, Faculty of Medicine, at KU Leuven in Belgium. She performed her doctoral studies in Denisa Wagner’s lab and received her PhD in Immunology from Harvard Medical School for her thesis titled “Neutrophil extracellular traps in thrombosis and inflammation.” Her work on PAD4’s contribution to NETs in cardiovascular disease includes a focus on deep vein thrombosis, sepsis, and cardiac fibrosis. Her research group, located at the Center for Molecular and Vascular Biology in Leuven, Belgium, focuses on the interplay between thrombosis and inflammation in cardiac disease, specifically in the development of heart failure. She is, as of 2022, Chair of the Scientific Subcommittee on Vascular Biology of the International Society on Thrombosis and Haemostasis, where she is currently leading an international standardization study on the measurement of NETs in human plasma samples.
12:20 - 12:50 |
Evolving Functions of Arginine Citrullination
Protein citrullination (deimination) is the post-translational modification of arginine to the non-coded amino acid citrulline, catalyzed by the peptidyl arginine deiminases (PADIs) enzyme family. Of the five PADIs, PADI2 is widely expressed, and it regulates essential normal and pathological cellular processes that impact multiple cancers. How PADI2 has evolved in mammals to gain its fundamental function is not fully understood. By performing a systematic evolutionary analysis, the group of researchers identified positively selected residues in PADI2, the majority of them are structurally exposed mainly on the N-terminal and middle domains of PADI2. Their data suggests that these residues have roles in maintaining the PADI2 interactions with cognate proteins. In particular, the researchers demonstrate experimentally that the positively selected leucine 162 (L162) encompassing loop in the middle domain participates in the interaction of PADI2 with the positive-transcription elongation factor (P-TEFb) complex, which is essential for the active transcription and cellular proliferation. Thus, the author will discuss this work on PADI2 evolution that revealed the function of the PADI2 non-catalytic domain in modulating transcription. This knowledge could be key to understanding the PADI2 function across several cancers as well as pinpointing potential targetable regions of the protein. Dr Priyanka Sharma, Montpellier Cancer Research Institute (IRCM), France
Dr Priyanka Sharma, Montpellier Cancer Research Institute (IRCM), FrancePriyanka Sharma (ORCID 0000-0003-3890-3590) is a biomedical scientist, who recently (November 2020) joined the French National Institute of Health and Medical Research, working at the Montpellier cancer research centre, France. She completed her Ph.D. in biomedical science in India followed by her postdoctoral training at Institute Pasteur, Paris, France, and the Centre for Genomic Regulation, Barcelona, Spain with availed fellowships from Novartis and Marie Curie foundations. Her young team is focused to understand the molecular mechanisms to understand the transcriptional and epigenetic plasticity in cancer. |
---|---|
12:50 - 13:00 | Discussion |
13:00 - 13:30 |
Essential role of non-histone protein citrullination in maintaining the stemness of ovarian cancer cells
There is growing evidence from basic to clinical studies that supports the crucial roles of PADIs-catalyzed protein citrullination associated with the onset and progression of cancers. In their previous studies, the authors have demonstrated that PADI2-catalyzed MEK1 citrullination activates ERK1/2 phosphorylation, which promotes IGF2BP1-mediated Sox2 mRNA stability, a key stemness-related factor, in endometrial cancer, thus enhancing a tumor-initiating cell phenotype. This novel finding indicated that PADIs-mediated kinases citrullination in tumours can affect the tumorigenesis thorough targeting cancer stem cells. Interestingly, in their recent study, the authors found that PADI1 enzymatic activity was also required to maintain the stemness characteristics and malignancy of ovarian cancer cells. Specifically, PADI1-catalyzed AKT2 citrullination facilitates its phosphorylation, which activates transcription factor CEBPB to promote the transcription of stemness genes. Meanwhile, the five-year survival rate of patients with high PADI1 expression in primary ovarian cancer was significantly lower than that of patients with low PADI1 expression, further highlighting the crucial role of PADI1 in the pathogenesis of ovarian cancer. Exploring the mechanism of drug resistance in ovarian cancer and seeking new effective therapeutic potential targets is of great significance to improve the survival rate of these patients. This study may help establish PADI1 as a novel therapeutic target. Dr Xuesen Zhang, Nanjing Medical University, China
Dr Xuesen Zhang, Nanjing Medical University, ChinaDr Xuesen Zhang, a Professor in the Department of Biochemistry and Molecular Biology at Nanjing Medical University. He received his Bachelor’s degree and Master’s degree from Dalian Medical University in 1999 and 2002 respectively. Upon completion of his doctorate in Chinese Academy of Sciences in 2005, Dr Zhang accepted his postdoctoral training at the University of Iowa. In 2007, he joined Professor Scott Coonrod at Cornell University, and received more comprehensive postdoctoral training in the study of citrullination and breast cancer. In 2013, he was appointed as a Principal Investigator in Nanjing Medical University. Dr Zhang’s research has mainly focused on the role of non-histone protein citrullination in regulating tumor cell signaling pathways. He was awarded Susan G Komen for the Cure postdoctoral fellowship in 2010, and the Distinguished Professor of Jiangsu Province, China in 2016. |
13:30 - 13:40 | Discussion |
13:40 - 14:10 | Break |
14:10 - 14:40 |
Unravelling the role of citrullination in inflammatory disease and cancer
Increasing evidence suggests that citrullination is a key process involved in inflammatory disease and cancer. The aim of this study is to understand the role of citrullination by identifying key citrullinated targets and relate this information to the disease context. E2F is a family of master transcription regulators involved in regulating diverse cellular fates. In previous studies the authors have found that the E2F1 subunit is regulated through post-translational events, which includes citrullination, mediated by peptidyl arginine deiminase (PAD) 4. Subsequently, they used genome-wide analysis to study gene expression changes dependent on PAD4 and E2F1 and identified an unexpected level of control on RNA processing together with citrullinated RNA binding proteins that mediate the events. Notably, important differences were apparent when either inflammatory or cancer cells were compared to normal cells. The results suggest that PAD4 has widespread effects on gene expression mediated through the E2F pathway and candidate RNA binding proteins, and that gene expression is affected at multiple levels, including transcription and RNA processing. Professor Nicholas La Thangue FRSE, FMedSci, Department of Oncology, Oxford University, UK
Professor Nicholas La Thangue FRSE, FMedSci, Department of Oncology, Oxford University, UKNick is Professor of Cancer Biology in the Oncology Department at Oxford University. He is a translational cancer biologist with a deep interest in developing novel therapeutics. He is a Fellow of the Royal Society of Edinburgh, the Academy of Medical Sciences, the European Academy of Cancer Science, the Lister Institute and Professorial Fellow of Linacre College Oxford. He has over 300 publications and is an inventor on numerous patents. |
14:40 - 14:50 | Discussion |
14:50 - 15:20 |
An update on protein citrullination in female rePADuctive tissues
Some of the first research in the peptidylarginine deiminase (PAD) biology field characterized these enzymes in the female reproductive tract and anterior pituitary gland. Anterior pituitary gland gonadotrope cells synthesize and secrete luteinizing hormone (LH) and follicle stimulating hormone (FSH), which are required for follicle development and ovulation in all female mammals. In mice, PAD2 expression is elevated in gonadotrope cells during the estrus phase of the estrous cycle, where it citrullinates histones. The research data shows that histone citrullination suppresses the expression of DiGeorge Syndrome Critical Region 8 (DGCR8) microprocessor complex subunit, a riboprotein required for canonical miRNA biogenesis. PAD mediated changes in DGCR8 expression in gonadotropes during the estrous cycle lead to fluctuations in miRNA biogenesis, which modulates female reproduction. The authors are also investigating the function of PADs and citrullinated proteins in the human cervicovaginal (CV) mucosa. Women have a 3-fold higher incidence of rheumatoid arthritis (RA) compared to men, and risk factors for RA include age of menarche, parity, and the postpartum period. RA can be clinically diagnosed by the presence of anti-citrullinated protein antibodies (ACPA) in blood. While studies support that ACPA form at mucosal sites, this work has focused on the lung, gingiva, or gut mucosa, none of which explains the sex differences underlying the increased prevalence of RA in women. The authors' work shows that fluid from the healthy CV mucosa contains active PAD enzymes, cit-proteins, and ACPA that fluctuate across the menstrual cycle. Using mass spectrometry, the authors identified the CV mucosa citrullinome, which differs between samples from healthy women and those at risk for and with RA. The research data suggests that PADs and cit-proteins are normally released at the CV mucosa during times of mucosal tissue disruption and inflammation; yet, as this process repeats with each menstrual cycle, during pregnancy and postpartum, it may increase the likelihood of RA in women. Professor Brian Cherrington, University of Wyoming, USA
Professor Brian Cherrington, University of Wyoming, USABrian Cherrington completed his undergraduate degree at Washington University in St Louis and then received a MSc and PhD in reproductive endocrinology from Colorado State University. In his first postdoctoral research at the University of California, San Diego, he investigated gene programs in anterior pituitary gonadotrope cells. He then completed a second postdoctoral research at Cornell University investigating the function of peptidylarginine deiminase (PAD) enzymes in the mammary gland and breast cancer. He joined the department of Zoology and Physiology at the University of Wyoming in 2011 and is currently an Associate Professor. His lab studies the function of PAD enzymes and citrullinated proteins in gonadotrope cells and the female reproductive tract. |
15:20 - 15:30 | Discussion |
15:30 - 16:00 |
Lightning talks
Poster presenters will be given the opportunity to apply to give a short talk. The selected poster abstracts will be available soon |
16:00 - 17:00 | Poster session |
Chair
Dr Maria Christophorou, Babraham Institute, UK
Dr Maria Christophorou, Babraham Institute, UK
Maria is a biomedical scientist interested in understanding how cell signaling inputs are translated into the epigenetic changes that underlie cell fate. She studied biology at MIT as a Fulbright Scholar and obtained a PhD in cancer biology from UCSF. As a postdoctoral fellow in epigenetics at the Gurdon Institute, University of Cambridge, she identified a novel role for protein citrullination in the establishment of pluripotency and described a mechanism by which it mediates chromatin decondensation. She is currently a Principal Investigator at the Babraham Institute in Cambridge, UK. The work of her team continues to focus primarily on protein citrullination, with the aim of understanding how it is regulated, the molecular mechanisms through which it modulates cell physiology and how its deregulation impacts on disease development. Maria’s work has been funded by fellowships from EMBO, HFSP, Wellcome Trust and Royal Society. She was awarded the Wellcome-Beit Prize in 2015.
08:00 - 08:30 |
Small molecule activation of protein citrullination
Citrullination has been associated with various types of diseases including cancer and autoimmune disorders, while its role is not fully clarified especially in cancer. During past decades, a number of small molecules targeting protein citrullination have been reported, while most of them are inhibitors but not activators. The talk will focus on small molecule activation of protein citrullination, identification of new substrate of citrullination, as well as a rational screening and validation of small molecules activation of protein citrullination based on a natural product library. Discovery of small molecule targeting protein citrullination would be attractive not only to cue citrullination-dependent diseases, but also allow development of pharmacological approaches to investigate the role of citrullination in disease progression. Dr Xisong Ke, Shanghai University of Traditional Chinese Medicine, China
Dr Xisong Ke, Shanghai University of Traditional Chinese Medicine, ChinaProfessor Xisong Ke is the Director of the Centre for Chemical Biology, Shanghai University of Traditional Chinese Medicine. He obtained his PhD degree in Biochemistry from Peking Union Medical College (PUMC) in 2005. After three years of postdoctoral training from 2006 to 2009 at the University of Bergen (UiB), Norway, he received a Bergen Medical Research Foundation (BMSF) researcher position in the Department of Clinical Science of UiB from 2010 to 2016. At the end of 2016, he moved to Shanghai University of Traditional Chinese Medicine, where his research interests include small molecule targeting protein translational modification (neddylation, ubiquitination and citrullination), discovery and development of natural products for targeted cancer therapy, as well as investigation of understudied proteins using pharmacological approaches. He has also served as a consulting editor of pharmacological research since 2019. |
---|---|
08:30 - 08:40 | Discussion |
08:40 - 09:10 |
A cyclic peptide toolkit to modulate PADI4 activity
Peptidyl arginine deiminase IV (PADI4) catalyses the citrullination of a wide range of substrates, with roles in neutrophil extracellular trap formation, chemokine signalling and establishment of pluripotency. Aberrant activity is implicated in a range of pathologies, including rheumatoid arthritis, multiple sclerosis, and various cancers, with emerging evidence suggesting PADI4 inhibition has significant therapeutic potential. In this talk, I will describe recent work to develop a toolkit of potent, selective cyclic peptide modulators of PADI4. We employed the RaPID (Random non-standard Peptide Integrated Discovery) system to isolate binders of PADI4 from starting libraries of up to 1013 genetically-barcoded cyclic peptides. From three parallel screens designed to target different protein conformations we identified a series of nanomolar PADI4 peptide binders, with diverse activities. A lead peptide was developed as a cell permeable PADI4 inhibitor, whilst another non-inhibitory peptide was pursued as an affinity probe. Further peptides were identified as first-in-class activators of PADI4 to low calcium conditions both in vitro and in cells. Together, the peptides provide a powerful toolkit for further elucidation of the function of PADI4 in both normal development and disease, with potential to provide a basis for downstream drug development. Dr Louise Walport, Imperial College London and The Francis Crick Institute, UK
Dr Louise Walport, Imperial College London and The Francis Crick Institute, UKLouise is a Lecturer in the Department of Chemistry at Imperial College London and a Group Leader at the Francis Crick Institute. In 2014, Louise obtained her doctorate from the University of Oxford under the supervision of Professor Chris Schofield and Prof. Christina Redfield, focussing on mechanistic studies of histone demethylases. Following further postdoctoral work in Oxford, she was awarded a Marie Skłodowska-Curie Global Fellowship to work in the group of Professor Hiroaki Suga at the University of Tokyo, where she developed an interest in cyclic peptides. She established her independent group in late 2018, where she continues to be interested in understanding enzyme-catalysed post-translational modifications and developing new approaches to probe these with cyclic peptide-based tools. |
09:10 - 09:20 | Discussion |
09:20 - 09:50 | Break |
09:50 - 10:20 |
Lightning talks
Poster presenters will be given the opportunity to apply to give a short talk. The selected poster abstracts will be available soon |
10:20 - 10:30 | Discussion |
10:30 - 11:00 |
Deimination in epidermal barrier and hair formation
The epidermis is a barrier for preventing the skin penetration of pathogens, exogenous molecules, including allergens and toxins, and UV radiation. It also avoids the uncontrolled loss of body water and solutes. For many years, the authors are interested in the role of citrullination in the homeostasis of the epidermal barrier, as well as in skin diseases. They identified several epidermal targets of peptidyl-arginine deiminase (PAD) 1 and 3, including members of the S100-fused type protein family. The authors showed how deimination controls their fate in the upper epidermis, and how this process is regulated by the external environment. Their data also suggest that deimination is a key regulator of autophagy processes associated with epidermal keratinocyte differentiation. The authors recently demonstrated that deimination rate is reduced in the epidermis of patients affected by psoriasis, a common inflammatory skin condition, through the action of IL-22. Deimination is also important in hair follicle formation, particularly the trichohyalin-PAD3-transglutaminase pathway. Indeed, they demonstrated that mutations in PADI3 are responsible for two hair disorders, the uncombable hair syndrome and a particular form of alopecia exclusively affecting women of African ancestry, the Central Centrifugal Cicatricial Alopecia. Dr Michel Simon, University of Toulouse, France
Dr Michel Simon, University of Toulouse, FranceDr Michel Simon got his PhD degree from the University of Geneva, Switzerland, in 1988 and subsequently moved to the Department of Ontogenesis and Molecular Genetics of Laval University in Quebec, Canada. In 1990, he moved to the Toulouse University, France. He was recruited as a tenured scientist by the National Institute for Health and Medical Research (INSERM) in 1998. He currently heads a team in the Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy, Inserm U1291 - CNRS U5051 - Toulouse University). He is interested for 20 years in the characterization of the late steps of keratinocyte terminal differentiation and in the importance of the epidermal barrier function in skin homeostasis and skin inflammatory diseases. In particular, he was one of the pioneers in the study of citrullination in human skin. He published more than 100 Pubmed references, (H-index = 38), as well as several book chapters and patents. |
11:00 - 11:10 | Discussion |
11:10 - 11:40 |
PAD4, histone citrullination and NETs in cardiovascular disease
Neutrophil extracellular traps can play a pathological role in human disease, having been shown to contribute to the detrimental host response in sepsis and in thrombus formation in both arterial and venous thrombosis. Citrullinated histones, generated during NET formation by the enzyme peptidylarginine deaminase 4 (PAD4) serve as useful biomarkers of ongoing NET formation. Studies using mice fully deficient in PAD4 showed a protection from thrombus formation in a model of deep vein thrombosis, reduced coagulation and immunothrombosis in systemic infection, yet no increase in bacteremia in a model of polymicrobial sepsis. The authors have also seen that PAD4-/- mice maintain normal cardiac function in aging or after pressure overload injury, which they have recently shown to be neutrophil-dependent. In addition to the direct effect of NETs, PAD4 released on NETs can also modify proteins involved in regulation of blood clotting, including the VWF-cleaving enzyme ADAMTS13. PAD4 therefore provides a potential therapeutic target for NET-related diseases involving immunothrombosis as a driving mechanism. Dr Kimberly Martinod, KU Leuven, Belgium
Dr Kimberly Martinod, KU Leuven, BelgiumKimberly Martinod is an assistant professor in the Department of Cardiovascular Sciences, Faculty of Medicine, at KU Leuven in Belgium. She performed her doctoral studies in Denisa Wagner’s lab and received her PhD in Immunology from Harvard Medical School for her thesis titled “Neutrophil extracellular traps in thrombosis and inflammation.” Her work on PAD4’s contribution to NETs in cardiovascular disease includes a focus on deep vein thrombosis, sepsis, and cardiac fibrosis. Her research group, located at the Center for Molecular and Vascular Biology in Leuven, Belgium, focuses on the interplay between thrombosis and inflammation in cardiac disease, specifically in the development of heart failure. She is, as of 2022, Chair of the Scientific Subcommittee on Vascular Biology of the International Society on Thrombosis and Haemostasis, where she is currently leading an international standardization study on the measurement of NETs in human plasma samples. |
11:40 - 11:50 | Discussion |
11:50 - 12:50 | Lunch |
Chair
Dr Priyanka Sharma, Montpellier Cancer Research Institute (IRCM), France
Dr Priyanka Sharma, Montpellier Cancer Research Institute (IRCM), France
Priyanka Sharma (ORCID 0000-0003-3890-3590) is a biomedical scientist, who recently (November 2020) joined the French National Institute of Health and Medical Research, working at the Montpellier cancer research centre, France. She completed her Ph.D. in biomedical science in India followed by her postdoctoral training at Institute Pasteur, Paris, France, and the Centre for Genomic Regulation, Barcelona, Spain with availed fellowships from Novartis and Marie Curie foundations. Her young team is focused to understand the molecular mechanisms to understand the transcriptional and epigenetic plasticity in cancer.
12:50 - 13:20 |
Global and site-specific mapping of the human citrullinome reveals broad scope of PADI4-induced citrullination
Citrullination refers to the conversion of arginine into the non-essential amino acid citrulline. Despite its importance in physiology and disease, global identification of citrullinated proteins and modification sites has remained challenging. Here, the authors combined mass spectrometry-based proteomics with differentiation of leukemia cell line into neutrophil-like cells to reveal a comprehensive atlas of regulated citrullination sites. Collectively, the authors identified >13.000 citrullination sites within >3.500 proteins allowing deduction of general principles about the mechanistic and cell biological aspects of citrullination function. Using quantitative proteomics the authors monitored citrullination changes in response to the PADI4-specific inhibitor GSK484, providing site-specific regulation of thousands of PADI4 substrates, including signature histone marks and numerous non-histone events on transcriptional regulators and chromatin-related signalling effectors. Collectively, the authors describe systems attributes of the human citrullinome, reveal the existence of thousands citrullinated autoantigens in neutrophil cells, and provide a resource framework for investigating PADI4-specific functions and substrates for years to come. Professor Michael Nielsen, The Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Denmark
Professor Michael Nielsen, The Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, DenmarkProfessor Michael L. Nielsen (MLN) obtained his PhD in ion physics from Uppsala University in 2007, and he subsequently joined the lab of Professor Matthias Mann at the Max-Planck Institute for postdoctoral training. In 2009, MLN established his research group at CPR focusing on developing novel proteomics methods and technologies for studying ‘not-so-well-characterized’ post-translational protein modifications (PTMs) on a systems-level approach. Despite the cellular modificome being highly complex only a small subset of the estimated 200 possible types of PTMs are currently amenable for analysis on a system-wide scale. Hence, the overarching aim of this is to elucidate the biological implications these emerging PTMs exert in human cells, while uncovering the functional impact they exert in cellular phenotypes and diseases. Key achievements is the development of proteomics strategies for systems-wide analysis of SUMOylation, Arginine methylation, ADP-ribosylation and Citrullination allowing his research group to study these PTMs in wide a range of cellular and biological conditions. |
---|---|
13:20 - 13:30 | Discussion |
13:30 - 14:00 |
Citrullination of neutrophil extracellular traps and autoimmunity
Neutrophil extracellular traps (NETs) are fibrous networks of chromatin and antibacterial proteins that are extruded from neutrophils in order to capture pathogens and prevent them from spreading. Soon after their identification in 2004 it was suggested that NETs might contain antigens capable of inducing autoimmune responses. NETs contain many autoantigenic molecules such as DNA, histones and other intracellular proteins that are usually shielded from the immune system, but become exposed when NETs are formed. NET formation can be categorized based on the effects of different NET-inducing stimuli and the dependence on citrullination, which particularly involves PAD4-mediated citrullination of histone H3. Using two distinct assays the authors investigated the reactivity of rheumatoid arthritis (RA) patient sera with NETs. Anti-NET antibodies were detected in 51% of the RA patients and this may at least in part be due to the frequent presence of anti-citrullinated protein antibodies (ACPA) in RA. Histone H3 citrullination appeared to be dependent on the NET-inducing stimulus and neutrophil protease activity reduced the levels of NET-associated citrullinated H3. Moreover, their data demonstrate that a large number of NET-associated autoepitopes can be removed by neutrophil proteases. The consequences for the autoimmune response against citrullinated proteins will be discussed. Professor Ger Pruijn, Radboud University Nijmegen, The Netherlands
Professor Ger Pruijn, Radboud University Nijmegen, The NetherlandsGer Pruijn received his PhD degree in Physiological Chemistry from the University of Utrecht in 1989. His interest in autoimmunity was raised during his postdoctoral work at the University of Nijmegen, which was awarded with a fellowship from the Royal Netherlands Academy of Arts and Sciences. He has a special interest in autoantibody-based diagnostics and autoantigenic macromolecular complexes. After an assistant professorship in Biochemistry (University of Nijmegen, 1997) and an associate professorship at the same university (2000), he was appointed as full professor in Biomolecular Chemistry at the Radboud University in 2006. Since 2006 he is head of the Department of Biomolecular Chemistry of the Institute of Molecules and Materials. Ger Pruijn has (co-)authored more than 250 peer-reviewed scientific papers, is co-inventor of 3 patents, co-founder of the companies ModiQuest and Novio Catalpa, and acted as consultant to several diagnostic companies. |
14:00 - 14:10 | Discussion |
14:10 - 14:30 | Break |
14:30 - 15:00 |
Insights into RA pathogenesis from the study of anti-PAD immune responses
Immune responses to peptidylarginine deiminase (PAD) enzymes, proteins that catalyze the post-translational deamination of arginine residues in a process known as citrullination, have been discovered in subsets of patients with rheumatoid arthritis (RA). Among these, anti-PAD4 immune responses are the most widely studied and include both autoreactive CD4+ T cell and autoantibody responses. Anti-PAD4 antibodies are present in 25-40% of RA patients, are detectable in the pre-clinical phase prior to disease diagnosis, and associate with erosive joint damage. A subset of anti-PAD4 antibodies cross-react with the related enzyme PAD3 (termed anti-PAD3/4 antibodies), and associate with the most severe erosive joint disease and presence of interstitial lung disease. Anti-PAD3/4 antibodies possess the unique ability to activate PAD4 upon binding, resulting in the increased citrullination of physiologic substrates. Anti-PAD4 and PAD3/4 antibodies cloned from patients with RA are able to bind directly to the surface of monocytes, via recognition of PAD4 expressed on the cell surface, and trigger pro-inflammatory chemokine secretion and exacerbation of inflammatory arthritis in the collagen-induced arthritis mouse model. The ability of anti-PAD4 antibodies to augment citrullination and activate monocytes suggests that they may be direct pathogenic players in amplifying disease in patients with RA. Dr Erika Darrah, Johns Hopkins University Medicine, USA
Dr Erika Darrah, Johns Hopkins University Medicine, USAErika Darrah PhD is an Associate Professor of Medicine at the Johns Hopkins University. After receiving her BS in Biology and Chemistry from Ursinus College, she pursued a PhD and postdoctoral training in Immunology at Johns Hopkins in the lab of Dr Antony Rosen. Her lab currently studies mechanisms that drive the development and propagation of autoimmune diseases, with a focus on translational applications and biomarker discovery in the human model. The four main areas of research in her lab include: (1) understanding the role of peptidylarginine deiminase (PAD) enzymes and anti-PAD immune responses in the pathogenesis of rheumatoid arthritis; (2) defining principles governing autoantigen processing and presentation and identifying resulting autoreactive T cells; and (3) identifying pathogenic pathways that drive the female bias of autoimmunity. |
15:00 - 15:10 | Discussion |
15:10 - 15:40 |
Protein citrullination is a novel therapeutic target for inflammatory diseases
The Protein Arginine Deiminases (PADs) hydrolyse arginine residues to form citrulline. This post-translational modification, termed citrullination, is upregulated in several autoimmune disorders including Rheumatoid Arthritis (RA), lupus, and Alzheimer’s disease. While these enzymes are important regulators of gene transcription, the full spectrum of biological activities is relatively underexplored. The author will discuss his development of pan and isozyme specific PAD inhibitors and their use in vitro and in vivo. Also, he will describe his development of phenylglyoxal-based probes, which chemoselectively react with citrulline to facilitate the labelling and enrichment of the RA-associated citrullinome. Notably, citrullination modulates the activity of metabolic enzymes and serine protease inhibitors (SERPINs), including nicotinamide N-methyltransferase and numerous SERPINs (eg C1 inhibitor, anti-thrombin, and anti-plasmin). Inhibition of SERPIN activity is highly significant as it triggers increased protease activity, thereby activating multiple processes including tissue remodelling, altered blood coagulation, and the activation of the complement cascade. Finally, the author will describe their efforts to site-specifically incorporate citrulline into proteins. Professor Paul Thompson, FRSC, University of Massachusetts Medical School, USA
Professor Paul Thompson, FRSC, University of Massachusetts Medical School, USAPaul Thompson is the Director of the Program in Chemical Biology at the University of Massachusetts Medical School. He is also a Professor in the Department of Biochemistry and Molecular Biotechnology. Paul is a world leader in the biology and biochemistry of the Protein Arginine Deiminases, a family of enzymes whose activity is increased in rheumatoid arthritis, inflammatory bowel disease, lupus, and cancer. In 2014, Paul founded Padlock Therapeutics to develop therapeutics that target these enzymes. This company was subsequently acquired by Bristol Myers Squibb. Paul received his BSc and PhD degrees from McMaster University and then performed postdoctoral research at Johns Hopkins. Paul began his independent career at the University of South Carolina before moving to Scripps Florida. Paul subsequently moved to the University of Massachusetts Medical School in August 2014. Paul has published more than 180 articles and is a Fellow of the Royal Society of Chemistry.
|
15:40 - 15:50 | Discussion |
15:50 - 16:10 |
Closing remarks and future directions
Dr Maria Christophorou, Babraham Institute, UK
Dr Maria Christophorou, Babraham Institute, UKMaria is a biomedical scientist interested in understanding how cell signaling inputs are translated into the epigenetic changes that underlie cell fate. She studied biology at MIT as a Fulbright Scholar and obtained a PhD in cancer biology from UCSF. As a postdoctoral fellow in epigenetics at the Gurdon Institute, University of Cambridge, she identified a novel role for protein citrullination in the establishment of pluripotency and described a mechanism by which it mediates chromatin decondensation. She is currently a Principal Investigator at the Babraham Institute in Cambridge, UK. The work of her team continues to focus primarily on protein citrullination, with the aim of understanding how it is regulated, the molecular mechanisms through which it modulates cell physiology and how its deregulation impacts on disease development. Maria’s work has been funded by fellowships from EMBO, HFSP, Wellcome Trust and Royal Society. She was awarded the Wellcome-Beit Prize in 2015. |